Philip Morisky, MBA, Ξ的动态

adhrence is a cooperation success and outcome

As a pediatric hematologist and oncologist, my focus is on delivering compassionate, comprehensive care to children battling complex blood disorders and cancers. Understanding the unique challenges faced by young patients, I aim to create a supportive environment where they can thrive. From refractory anemias and ITP to leukemias, lymphomas, and various childhood cancers, each condition requires a tailored approach to treatment. Early diagnosis, effective therapies, and holistic support play crucial roles in the journey toward recovery. By empowering children and their families, I strive to make a significant difference in their lives, offering not just medical care but also emotional support during tough times. It’s essential to spread awareness about these conditions so families can seek timely medical attention and understand the importance of specialized care. Let’s continue to stand together in the fight against childhood blood disorders and cancers, ensuring a brighter, healthier future for every young warrior. #PediatricOncology #HematologyCare #ChildhoodCancerAwareness #BloodDisorders #Leukemia #Lymphoma #ChildhoodCancers #ITP #RefractoryAnemias #CompassionateCare #HolisticSupport #YoungWarriors #ChildHealth #CancerSupport #PediatricCare #EarlyDiagnosis #CancerAwareness #SupportForFamilies #EmpoweringKids #HealingJourney #SpecializedCare #HealthcareHeroes #FightingCancer #KidsHealth #PaediatricOncology #DrKrutikaKurhadeGoel #childhealthcare #pediatrichematologyoncology #bestpediatriconcologyinchandigarh #bestpediatriconcologistinmohali

Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial) ### Summary This study examined adverse events associated with methylphenidate (MPH) treatment for apathy in Alzheimer's Disease (AD) compared to placebo, focusing on weight loss, vital signs, falls, and insomnia. ### Highlights - ?? MPH treatment in AD patients for apathy is relatively safe - ?? Statistically significant weight loss associated with MPH use - ?? No differences in blood pressure changes between MPH and placebo groups - ?? More participants in the MPH group reported falls compared to the placebo group - ?? No significant differences in post-baseline insomnia between treatment groups - ?? No instances of serious cardiovascular events were reported - ?? Clinicians advised to monitor weight during MPH treatment #AlzheimersDisease #Apathy #Methylphenidate #AdverseEvents #Geriatrics #WeightLoss #Falls #Insomnia #CardiovascularEvents #MedicalResearch

A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: a randomized double-blind clinical trial ### Summary This study compared the efficacy of cinnarizine and amitriptyline in pediatric migraine prophylaxis, showing that both medications are effective but amitriptyline may be preferable due to faster onset of action and longer-lasting effects. ### Highlights - ?? Pediatric migraine prophylaxis compared: cinnarizine vs. amitriptyline - ?? Amitriptyline group showed more effective reduction in headache frequency and duration - ?? No significant difference in severity improvement and reducing disability score between the two groups - ?? Both medications effective in ameliorating migraine headaches and related disabilities - ?? Amitriptyline may be preferred option over cinnarizine based on study results - ?? Safety profiles of both medications were assessed with no serious adverse events observed #PediatricMigraine #MigraineProphylaxis #Amitriptyline #Cinnarizine #HeadacheReduction #ClinicalTrials

?? **Transforming Pediatric Oncology with Palliative Care** ?? In pediatric oncology, palliative care plays a vital role from the very first day of diagnosis. It’s not a sign of giving up; rather, it’s about providing comprehensive support to patients and their families. Engaging palliative care early on ensures that children and their families receive emotional, physical, and psychological care throughout the journey. However, there remains a significant gap in knowledge among oncologists regarding palliative care. Many still misconceive it as solely end-of-life planning, when in reality, it encompasses pain management, symptom relief, and improving quality of life, irrespective of the stage of illness. We must work together to shift this mindset. Integrating palliative care from the beginning can enhance treatment experiences and outcomes. Let’s advocate for better education and understanding among healthcare professionals to ensure that every child and family benefits from this essential aspect of care. #PediatricOncology #PalliativeCare #HealthcareTransformation #QualityOfLife #SupportFromDayOne

FibroScan for Pediatric Liver Disorders: Special Considerations -?Uniscan Diagnostics Non-Invasive and Child-Friendly: FibroScan is a non-invasive diagnostic tool that measures liver stiffness, making it particularly suitable for pediatric patients who may find invasive procedures distressing. At Uniscan Diagnostics, special consideration is given to creating a child-friendly environment, ensuring that young patients feel comfortable and at ease during the procedure. This approach helps in obtaining accurate results without causing unnecessary stress or discomfort to the child. Tailored Approach for Pediatric Patients: The use of FibroScan in pediatric liver disorders requires adjustments in technique and interpretation of results, as children’s liver stiffness values differ from those of adults. Uniscan Diagnostics employs pediatric specialists who are trained to perform and interpret FibroScan results in children. They consider factors such as the child’s age, growth stage, and specific liver condition to provide precise and reliable assessments. Comprehensive Care and Follow-Up: At Uniscan Diagnostics, FibroScan is integrated into a broader framework of comprehensive care for pediatric liver disorders. The facility ensures thorough follow-up and monitoring of liver health in young patients, allowing for early detection and timely intervention. This continuous care approach helps in managing chronic liver conditions effectively and improving long-term outcomes for pediatric patients. Best-in -Class Clinical laboratory Services ??Call us at +91 875 402 8362 or visit our website https://uniscanlabs.com?for more information. #fibroscan #liver #health #fattyliver #liverscan #edgarmora #vomiting #endoscopy #diabetes #highcholestarol #hepatits #alcoholicliver #nausea #swellingoverlegs #gastromedical #primehospitalpanipat #lossofappetite #diarrhea #fatigue #yellowskin #nafld #liverproblem #liverinflammation #hepatitsb #livertips #healtyliver #colonoscopia #endoscopia #free #liverhealth

?? ?? Proud to share a new article exploring the development of our digital health intervention - BMT4me?, a mobile health app designed to enhance medication adherence in children undergoing hematopoietic stem cell transplant (HCT). With non-adherence rates alarmingly high (52-73%) in pediatric HCT due to complex regimens and forgetfulness, this app is a critical step forward. ?? What’s Unique? We have developed BMT4me? using a user-centered, mixed methods approach, with continuous feedback from the people who matter most: caregiver-child dyads, healthcare providers, community advocates and experts across disciplines. Through iterative design and cross-phase testing, BMT4me? evolved to meet the real needs of families and medical teams. ?? Results So Far High Usability: Healthcare providers rated the app with an impressive SUS score of 84.2 (well above the 68 average). Key Themes: Engagement, ease of use, and safety were identified as strengths. ???? Impact on Practice The BMT4me? app has the potential to significantly improve medication adherence in pediatric HCT, ultimately reducing life-threatening risks for these young patients. As pilot feasibility testing with caregivers continues, we’re excited about the future implications for integrating digital health tools like BMT4me? into clinical care. ?? Looking Ahead: With our further NIH-funded research examining the use of BMT4me? in HCT patients during the acute phase, and with spanish speaking families, we will guide how digital interventions can support high-risk patients with complex regimens, making a meaningful difference in their health outcomes. Check out the full article in the link below to learn more about this innovative approach to pediatric care and how digital health is transforming patient support! https://lnkd.in/e5CtwUu5 #DigitalHealth #PediatricOncology #mHealth #MedicationAdherence #HealthcareInnovation #nationwidekids #research

#NIRS Monitoring has been widely used with #ECMO in the neonatal/pediatric populations. It is great to see this study demonstrate the utility of including this information in the adult ECMO patient populations. Especially the sub-group of VA ECMO. https://lnkd.in/efnRbA5H

A pooled safety and efficacy analysis of data from 3 clinical studies demonstrated that evolocumab was well tolerated, with no new safety concerns identified for pediatric patients with homozygous familial hypercholesterolemia (HoFH). View the complete article below ?? #HomozygousFamilialHypercholesterolemia #HoFH #Pediatrics

Have you ever contemplated the effectiveness of SGLT2 inhibitors in elderly or frail patients suffering from type 2 diabetes and heart failure? A systematic review and meta-analysis has shed significant light on this topic. Whilst SGLT2 inhibitors do not notably decrease HbA1c levels, they are indeed making a substantial difference - mitigating all-cause mortality, cardiac death, and hospitalisation due to heart failure. The caveat in this review? Their impact on macrovascular events, the progression of renal diseases, and other serious complications remains minimal in the frail elderly. These inhibitors are not leading to an increase in thromboembolic events or diabetic ketoacidosis in the frail elderly. This study underlines the imperative for clinicians to look beyond mere 'glycemic control'. SGLT2 inhibitors, owing to their potential cardiovascular benefits, could potentially revolutionise the treatment of elderly or frail patients afflicted by heart failure. Our pursuit of knowledge does not end here. It is paramount to undertake further research to evaluate the long-term effects and safety of SGLT2 inhibitors in these susceptible populations. It is essential to adopt a multidisciplinary strategy when making decisions about managing older individuals or those with frailty who have both Type 2 Diabetes Mellitus and Heart Failure. Moreover, factors such as co-morbidities, disability, frailty, expected lifespan, patient preferences, and treatment objectives should all be taken into account when devising a treatment strategy for this demographic. Your thoughts are valuable to this ongoing discourse. Do share your insights or experiences on using SGLT2 inhibitors in the comments. Also, don't forget to like, share this post with your peers and follow for more updates on this significant subject. Let's start a conversation that could potentially change lives. #sglt2inhibitors #frailelderly #geriatrics #heartfailure #journalreview